within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DC02_Cefuroxime;

model Cefuroxime
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.333333333333333e-07,
    adminDuration = 600,
    adminMass = 750 / 1000000,
    adminCount = 1,
    Vd = 0.009300000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0074,
    k12 = 1.6944444444444442e-06,
    k21 = 1.6944444444444442e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefuroxime</td></tr><tr><td>ATC code:</td><td>J01DC02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>750</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>9.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.0</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefuroxime is a second-generation cephalosporin antibiotic with broad-spectrum activity against gram-positive and gram-negative bacteria. It is used to treat various infections, including respiratory tract, urinary tract, skin and soft tissue infections. Cefuroxime is approved and widely used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single intravenous dose.</p><h4>References</h4><ol><li><p>Janssen, PK, et al., &amp; le Noble, JL (2016). Population Pharmacokinetics of Cefuroxime in Critically Ill Patients Receiving Continuous Venovenous Hemofiltration With Regional Citrate Anticoagulation and a Phosphate-Containing Replacement Fluid. <i>Therapeutic drug monitoring</i> 38(6) 699–705. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000000330\">10.1097/FTD.0000000000000330</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27494946/\">https://pubmed.ncbi.nlm.nih.gov/27494946</a></p></li><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Carlier, M, et al., &amp; De Waele, JJ (2014). Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. <i>The Journal of antimicrobial chemotherapy</i> 69(10) 2797–2803. DOI:<a href=\"https://doi.org/10.1093/jac/dku195\">10.1093/jac/dku195</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24917580/\">https://pubmed.ncbi.nlm.nih.gov/24917580</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DC02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefuroxime;
